Baseline | 1-year FU | 2-year FU | 3-year-FU | |
---|---|---|---|---|
n | 953 | 850 | 805 | 761 |
JIA categories | ||||
Oligoarthritis, n (%) | 441 (46.3%) | – | – | – |
Persistent oligoarthritis, n (%) | 315 (37.1%) | – | 253 (33.3%) | |
Extended oligoarthritis, n (%) | 74 (8.7%) | – | 98 (12.9%) | |
RF-negative polyarthritis, n (%) | 250 (26.2%) | 226 (26.6%) | – | 205 (27.0%) |
RF-positive polyarthritis, n (%) | 16 (1.7%) | 15 (1.8%) | – | 15 (2.0%) |
Enthesitis-related arthritis, n (%) | 100 (10.5%) | 92 (10.8%) | – | 75 (9.9%) |
Psoriatic arthritis, n (%) | 40 (4.2%) | 41 (4.8%) | – | 35 (4.6%) |
Systemic-onset JIA, n (%) | 35 (3.7%) | 29 (3.4%) | – | 28 (3.7%) |
Undifferentiated arthritis, n (%) | 71 (7.5%) | 58 (6.9%) | – | 51 (6.7%) |
Disease activity | ||||
PGA (NRS 0–10), mean (SD) | 3.8 (2.6) | 1.0 (1.5) | 0.8 (1.4) | 0.8 (1.3) |
cJADAS-10 (0–30), mean (SD) | 9.8 (6.2) | 3.4 (4.0) | 2.8 (3.4) | 2.7 (3.6) |
Inactive disease, n (%) | 56 (6.0%) | 288 (39.8%) | 309 (46.8%) | 297 (52.0%) |
Minimal disease activity, n (%) | 24 (2.6%) | 89 (12.3%) | 85 (12.9%) | 64 (11.2%) |
Moderate disease activity, n (%) | 159 (17.0%) | 218 (30.2%) | 175 (26.5%) | 132 (23.1%) |
High disease activity, n (%) | 698 (74.5%) | 128 (17.7%) | 92 (13.9%) | 78 (13.7%) |
Parent’s reported outcomes | ||||
Functional status (CHAQ; range 0–3), mean (SD) | 0.6 (0.7) | 0.3 (0.5) | 0.2 (0.5) | 0.2 (0.5) |
FaBel (total scale; range 0–4), mean (SD)a | 1.7 (0.4) | – | – | – |
Treatment | ||||
NSAIDs, n (%) | 800 (84.0%) | 289 (37.8%) | 191 (26.1%) | 150 (22.4%) |
Systemic glucocorticoids, n (%) | 230 (24.1%) | 83 (10.9%) | 49 (6.7%) | 32 (4.8%) |
DMARDs, n (%) | 394 (41.3%) | 493 (64.5%) | 427 (58.3%) | 390 (58.2%) |
csDMARDs, n (%) | 387 (40.6%) | 454 (59.4%) | 350 (47.8%) | 313 (46.7%) |
MTX, n (%) | 364 (38.2%) | 422 (55.2%) | 324 (44.2%) | 285 (42.5%) |
Sulfasalazine, n (%) | 19 (2%) | 22 (2.9%) | 12 (1.6%) | 11 (1.6%) |
bDMARDs, n (%) | 38 (4.0%) | 156 (20.4%) | 179 (24.4%) | 163 (24.3%) |
Etanercept, n (%) | 21 (2.2%) | 86 (11.3%) | 105 (14.3%) | 86 (12.8%) |
Adalimumab, n (%) | 7 (0.7%) | 35 (4.6%) | 37 (5.1%) | 46 (6.9%) |